Sarah Boyce
Chief Executive Officer presso AVIDITY BIOSCIENCES, INC.
Patrimonio netto: 4 M $ in data 31/03/2024
Profilo
Sarah Boyce is currently the President, Chief Executive Officer & Director at Avidity Biosciences, Inc. She is also an Independent Director at OmniAb Operations, Inc. and a Director at OmniAb, Inc. Ms. Boyce has previously worked as an Independent Director at Ligand Pharmaceuticals, Inc., Berkeley Lights, Inc., and Akcea Therapeutics, Inc. She was also the Chief Business Officer at Ionis Pharmaceuticals, Inc., VP & Head-International Business Strategy at Forest Laboratories, Inc., VP-Global & Head-Nephrology Therapeutics at Alexion Pharmaceuticals, Inc., and Vice President-Global Program at Novartis AG.
Ms. Boyce received her undergraduate degree from The University of Manchester.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
AVIDITY BIOSCIENCES INC
0.14% | 02/04/2024 | 112 117 ( 0.14% ) | 3 M $ | 31/03/2024 |
OMNIAB, INC.
0.07% | 23/06/2023 | 82 190 ( 0.07% ) | 445 470 $ | 31/03/2024 |
| 01/11/2022 | 2 892 ( 0.02% ) | 211 405 $ | 31/03/2024 |
Posizioni attive di Sarah Boyce
| Società | Posizione | Inizio |
|---|---|---|
| AVIDITY BIOSCIENCES, INC. | Chief Executive Officer | 01/10/2019 |
| OMNIAB, INC. | Director/Board Member | 01/11/2022 |
OmniAb Operations, Inc.
 OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Director/Board Member | - |
Precedenti posizioni note di Sarah Boyce
| Società | Posizione | Fine |
|---|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Director/Board Member | 01/11/2022 |
Berkeley Lights, Inc.
 Berkeley Lights, Inc. Packaged SoftwareTechnology Services Berkeley Lights, Inc. engages in rapid development and commercialization of biotherapeutics and other cell-based products. Its platform captures deep phenotypic, functional and genotypic information for tens of thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. It operates through the following geographical segments: North America, Asia Pacific, and Europe. The company was founded by Igor Y. Khandros, William H. Davidow, Michael E. Marks, and Ming C. Wu on April 5, 2011 and is headquartered in Emeryville, CA. | Director/Board Member | 01/05/2022 |
| AKCEA THERAPEUTICS, INC. | President | 23/09/2019 |
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/04/2018 |
| FOREST LABORATORIES, INC. | Corporate Officer/Principal | 01/01/2014 |
Formazione di Sarah Boyce
| The University of Manchester | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| AVIDITY BIOSCIENCES, INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| OMNIAB, INC. | Commercial Services |
| Aziende private | 5 |
|---|---|
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Berkeley Lights, Inc.
Berkeley Lights, Inc. Packaged SoftwareTechnology Services Berkeley Lights, Inc. engages in rapid development and commercialization of biotherapeutics and other cell-based products. Its platform captures deep phenotypic, functional and genotypic information for tens of thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. It operates through the following geographical segments: North America, Asia Pacific, and Europe. The company was founded by Igor Y. Khandros, William H. Davidow, Michael E. Marks, and Ming C. Wu on April 5, 2011 and is headquartered in Emeryville, CA. | Technology Services |
OmniAb Operations, Inc.
OmniAb Operations, Inc. BiotechnologyHealth Technology OmniAb Operations, Inc. operates as a drug discovery company. It provides pharmaceutical industry partners access to antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform includes the Biological Intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse, that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company is headquartered in Emeryville, CA. | Health Technology |
- Borsa valori
- Insiders
- Sarah Boyce
